￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Akatinib/Axi-Cel produces initial response in relapsed/refractory B-cell lymphoma

2026-02-01 22:25:32

Check Details
Is acotinib/acalabrutinib covered by medical insurance?

2026-02-01 22:25:32

Check Details
Side effects of acalatinib/acalatinib targeted drugs

2026-02-01 22:25:32

Check Details
Acalatinib/Acalatinib’s relationship with AstraZeneca

2026-02-01 22:25:32

Check Details
How much does acalatinib cost per month?

2026-02-01 22:25:32

Check Details
Acalatinib/Acalatinib and Upapatinib

2026-02-01 22:25:32

Check Details
Current status of medical insurance coverage and patient reimbursement guidelines for acalatinib/acalabrutinib

2026-02-01 22:25:32

Check Details
Potential risks and countermeasures of acalatinib/acalatinib targeted drugs

2026-02-01 22:25:32

Check Details
Acalatinib/Acalabrutinib: AstraZeneca’s innovative anti-cancer drug

2026-02-01 22:25:32

Check Details
Discussion on the monthly treatment cost of acalatinib/acalatinib

2026-02-01 22:25:32

Check Details
Acotinib/Acalabrutinib and Upadatinib: Therapeutic areas and comparison of effects of the two drugs

2026-02-01 22:25:32

Check Details
Is acotinib/acalabrutinib immune or targeted?

2026-02-01 22:25:32

Check Details
Category
相关知识